ANP (Atrial Natriuretic Peptide) vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | PT-141 (Bremelanotide) |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 1.8 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–4 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
ANP (Atrial Natriuretic Peptide), PT-141 (Bremelanotide) are both commonly used for:
Which Has Stronger Evidence?
- Recovery & Healing: ANP (Atrial Natriuretic Peptide) has stronger research support.
| Goal | ANP (Atrial Natriuretic Peptide) | PT-141 (Bremelanotide) |
|---|---|---|
| Recovery & Healing | medium | low |
Key Studies
ANP (Atrial Natriuretic Peptide)
- Atrial natriuretic peptide (ANP) modulates stress-induced autophagy in endothelial cells.
Biochimica et biophysica acta. Molecular cell research, 2025
- C-atrial natriuretic peptide (ANP)(4-23) attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice.
Experimental cell research, 2023
- Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.
Hypertension (Dallas, Tex. : 1979), 2021
PT-141 (Bremelanotide)
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Journal of sex research, 2024
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal of women's health (2002), 2022
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Neurology international, 2022
Ready to Learn More?
Looking for trusted sources?